{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:56:27Z","timestamp":1770814587653,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The 2023 EULAR guidelines for systemic sclerosis (SSc) recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed data from a Japanese hospital claims database (2020\u20133), identifying patients with SSc disease codes (ICD-10\u00a0M34.x) and\/or ILD codes. Patients with coexisting autoimmune disease codes were also included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 14,522 SSc patients, 2080 (14.3%) received small-molecule drugs and 618 (4.3%) received biologics. For SSc, common first small-molecule drugs were methotrexate (24.2%), nintedanib (19.5%), tacrolimus (17.9%), and MMF (16.8%); common first biologics were rituximab (44.2%) and tocilizumab (29.1%). Of 4890 SSc-ILD patients, 1081 (22.1%) received small-molecule drugs and 282 (5.8%) received biologics. For SSc-ILD, common first small-molecule drugs were nintedanib (30.8%), tacrolimus (20.9%), and MMF (18.3%); common first biologics were rituximab (51.8%) and tocilizumab (25.2%). Rituximab showed the greatest increase in use for both SSc and SSc-ILD between 2020 and 2023. Common subsequent treatments following rituximab or intravenous cyclophosphamide (which are typically administered for a limited duration) were nintedanib, MMF, and rituximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recent actual drug use in Japan has been aligning increasingly closely with the EULAR recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf082","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:26:40Z","timestamp":1757417200000},"page":"39-48","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database"],"prefix":"10.1093","volume":"36","author":[{"given":"Takashi","family":"Funatogawa","sequence":"first","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Mii","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Aoki","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Hoshiba","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd , 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2026021103564037700_ref1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026021103564037700_ref2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021103564037700_ref3","author":"Japan Intractable Diseases Information Center (in Japanese)"},{"key":"2026021103564037700_ref4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021103564037700_ref5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2026021103564037700_ref6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026021103564037700_ref7","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021103564037700_ref8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026021103564037700_ref9","volume-title":"Clinical Practice Guidelines for Systemic Sclerosis, 2025 (in Japanese)","author":"Pediatric Rheumatology Association of Japan, Japanese Dermatological Association, Japan College of Rheumatology","year":"2025"},{"key":"2026021103564037700_ref10","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026021103564037700_ref11","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021103564037700_ref12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"2026021103564037700_ref13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026021103564037700_ref14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026021103564037700_ref15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021103564037700_ref16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026021103564037700_ref17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/mr\/roab111","article-title":"Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database","volume":"32","author":"Funatogawa","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026021103564037700_ref18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/mr\/roac055","article-title":"Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database","volume":"33","author":"Narita","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026021103564037700_ref19","author":"Medical Data Vision Co., Ltd"},{"key":"2026021103564037700_ref20","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/rheumatology\/keaa547","article-title":"Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026021103564037700_ref21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1513\/AnnalsATS.202301-053OC","article-title":"Cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Barnes","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026021103564037700_ref22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","article-title":"Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Ghazipura","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026021103564037700_ref23","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/1346-8138.14189","article-title":"Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide","volume":"45","author":"Numajiri","year":"2018","journal-title":"J Dermatol"},{"key":"2026021103564037700_ref24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026021103564037700_ref25","volume-title":"A Study of Cases with Concurrent Systemic Sclerosis and Rheumatoid Arthritis in Our Department (in Japanese)","author":"Hattori","year":"2012"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf082\/64235651\/roaf082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/39\/64235651\/roaf082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/39\/64235651\/roaf082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:56:51Z","timestamp":1770800211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/1\/39\/8250530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,10]]},"published-print":{"date-parts":[[2025,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf082","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,10]]}}}